These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 23479468)
1. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Charles JA; Tremlett H; Lu E; Guimond C; Sadovnick AD Neurology; 2013 Mar; 80(11):1068-9. PubMed ID: 23479468 [TBL] [Abstract][Full Text] [Related]
2. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738 [TBL] [Abstract][Full Text] [Related]
3. [Disease modifying drugs in multiple sclerosis and pregnancy]. Tur C; Tintoré M; Aguilera C Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277 [No Abstract] [Full Text] [Related]
4. Glatiramer acetate during early pregnancy: A prospective cohort study. Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804 [TBL] [Abstract][Full Text] [Related]
5. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Piscolla E; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; La Mantia L; Mancardi G; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP BMC Neurol; 2012 Oct; 12():124. PubMed ID: 23088447 [TBL] [Abstract][Full Text] [Related]
7. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Thiel S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K Mult Scler; 2016 May; 22(6):801-9. PubMed ID: 26920382 [TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis disease-modifying therapy and pregnancy. Miller AE Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870 [No Abstract] [Full Text] [Related]
9. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. Salminen HJ; Leggett H; Boggild M J Neurol; 2010 Dec; 257(12):2020-3. PubMed ID: 20625758 [TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Weber-Schoendorfer C; Schaefer C Mult Scler; 2009 Sep; 15(9):1037-42. PubMed ID: 19692433 [TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation. Fragoso YD Expert Opin Drug Saf; 2014 Dec; 13(12):1743-8. PubMed ID: 25176273 [TBL] [Abstract][Full Text] [Related]
12. Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate. Windhagen A; Maniak S; Marckmann S; Lindert RB; Heidenreich F; Blasczyk R J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):415-6. PubMed ID: 11181881 [No Abstract] [Full Text] [Related]
13. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Fragoso YD; Boggild M; Macias-Islas MA; Carra A; Schaerer KD; Aguayo A; de Almeida SM; Alvarenga MP; Alvarenga RM; Alves-Leon SV; Arruda WO; Brooks JB; Comini-Frota ER; Ferreira ML; Finkelsztejn A; Finkelsztejn JM; de Freitas LD; Gallina AS; da Gama PD; Georgetto S; Giacomo MC; Gomes S; Gonçalves MV; Grzesiuk AK; Kaimen-Maciel DR; Lopes J; Lourenco GA; Malfetano FR; Morales NM; Morales Rde R; Oliveira CL; Onaha P; Patroclo C; Ribeiro SB; Ribeiro TA; Salminen HJ; Santoro P; Seefeld M; Soares PV; Tarulla A; Vasconcelos CC Clin Neurol Neurosurg; 2013 Feb; 115(2):154-9. PubMed ID: 22633835 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Mahurkar S; Suppiah V; O'Doherty C Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284 [TBL] [Abstract][Full Text] [Related]
16. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. Lopez-Leon S; Geissbühler Y; Sabidó M; Turkson M; Wahlich C; Morris JK J Neurol; 2020 Sep; 267(9):2721-2731. PubMed ID: 32444984 [TBL] [Abstract][Full Text] [Related]
17. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Ghezzi A; Annovazzi P; Portaccio E; Cesari E; Amato MP Expert Rev Clin Immunol; 2013 Jul; 9(7):683-91; quiz 692. PubMed ID: 23899239 [TBL] [Abstract][Full Text] [Related]
18. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Lu E; Wang BW; Guimond C; Synnes A; Sadovnick AD; Dahlgren L; Traboulsee A; Tremlett H Expert Rev Neurother; 2013 Mar; 13(3):251-60; quiz 261. PubMed ID: 23448215 [TBL] [Abstract][Full Text] [Related]
19. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)]. Federal service on surveillance in healthcare and social development (Roszdravnadzor) Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163 [No Abstract] [Full Text] [Related]
20. Glatiramer acetate in multiple sclerosis. Mezzapesa DM; Rovaris M; Filippi M Expert Rev Neurother; 2005 Jul; 5(4):451-8. PubMed ID: 16026228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]